- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05282004
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
An Open-label, Single-arm, Multicenter Study in Patients With Neovascular Age-related Macular Degeneration to Evaluate the Safety of SOK583A1 (40 mg/mL), a Proposed Aflibercept Biosimilar Product, Provided in a Vial Kit
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Poway, California, United States, 92064
- Sandoz Investigational Site
-
-
Georgia
-
Marietta, Georgia, United States, 30060
- Sandoz Investigational Site
-
-
Illinois
-
Oak Forest, Illinois, United States, 60452
- Sandoz Investigational Site
-
-
New York
-
Liverpool, New York, United States, 13088
- Sandoz Investigational Site
-
-
Virginia
-
Lynchburg, Virginia, United States, 24502
- Sandoz Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients ≥ 50 years of age at baseline
- Patients diagnosed with nAMD (uni- or bilateral)
- Patients already under IVT Eylea treatment (last injection of the induction period or maintenance phase)
- Willing and able to comply with all study procedures, and be likely to complete the study
- Signed informed consent must be obtained before any assessment is performed
Exclusion Criteria:
- Active, suspected or recent (within 4 weeks) intraocular inflammation (grade trace or above) in the study eye at baseline, which is of clinical significance according to the investigator's judgment, such as active infections of the anterior segment; this includes conjunctivitis (except mild blepharitis), keratitis, scleritis, idiopathic or autoimmune associated uveitis or endophthalmitis
- Any uncontrolled ocular hypertension or glaucoma in the study eye (defined as IOP ≥ 26 mmHg, despite treatment with anti-glaucomatous medication)
- History of a medical, ocular or non-ocular condition, that in the judgment of the investigator, would preclude a safe administration of investigational product
- Visual acuity Score (VAS) worse than 20/200 on a Snellen chart, the generally accepted level of legal blindness
- Topical ocular corticosteroids administered for at least 30 consecutive days within 3 months prior to screening
- Systemic treatment with long-acting corticosteroids (more than 10 mg prednisolone equivalent) within 3 months prior to screening Current or planned use of systemic medications known to be toxic to the lens, retina or optic nerve, including deferoxamine, chloroquine/hydroxychloroquine, tamoxifen, phenothiazines and ethambutol
- Any invasive intraocular surgery, prior long-acting therapeutic agent, or ocular drug release device implantation (approved or investigational) in the study eye any time during the past 3 months
- Receipt of any systemic anti-VEGF within the last 6 months prior to enrollment
- Uncontrolled hypertension (defined as a systolic value ≥ 160 mmHg or diastolic value ≥ 100 mmHg at Screening)
- Participants who do not comply with the local COVID-19 regulations of the study site
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SOK583A1
SOK583A1 will be provided in a vial kit, with 40 mg/mL of aflibercept solution for IVT injection (2 mg/0.05
mL)
|
SOK583A1 will be provided in a vial kit, with 40 mg/mL of aflibercept solution for IVT injection (2 mg/0.05
mL)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Ocular Treatment Emergent Adverse Events
Time Frame: 31 days
|
Number of participants with ocular treatment emergent adverse events were reported.
|
31 days
|
Number of Participants With Non-ocular Treatment Emergent Adverse Events
Time Frame: 31 days
|
Number of participants with non-ocular treatment emergent adverse events were reported.
|
31 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSOK583A12303
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neovascular Age-related Macular Degeneration (nAMD)
-
AbbVieAbbVieEnrolling by invitationGene Therapy | AMD | nAMD | Wet AMD | Neovascular Age-Related Macular Degeneration (nAMD) | wAMDUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
AsclepiX Therapeutics, Inc.TerminatedNeovascular Age-Related Macular Degeneration (nAMD)United States
-
Ocugenix CorporationNot yet recruitingNeovascular Age-related Macular Degeneration (nAMD)United States
-
Aerie PharmaceuticalsAlcon ResearchRecruitingNeovascular Age-related Macular Degeneration (nAMD)United States
-
Kyowa Kirin, Inc.RecruitingNeovascular Age-Related Macular Degeneration (nAMD)United States, Japan, Korea, Republic of, Australia
-
Hoffmann-La RocheRecruitingNeovascular Age-related Macular Degeneration (nAMD)Belgium, Korea, Republic of, Germany, Spain, United Kingdom, Australia, Italy, Argentina, Israel, Austria, Brazil, France, Singapore, Switzerland, Taiwan, Turkey
-
Novartis PharmaceuticalsActive, not recruitingNeovascular Age-related Macular Degeneration (nAMD)Portugal
-
SandozCompletedNeovascular Age-related Macular Degeneration (nAMD)United States
-
HuidaGene Therapeutics Co., Ltd.Eye & ENT Hospital of Fudan University; Tianjin Medical University Eye HospitalRecruitingNeovascular Age-related Macular Degeneration(nAMD)China
Clinical Trials on SOK583A1
-
SandozCompletedNeovascular Age-related Macular DegenerationUnited States, Bulgaria, Czechia, Australia, Austria, France, Germany, Hungary, Israel, Japan, Latvia, Lithuania, Poland, Portugal, Slovakia, Spain
-
SandozCompletedNeovascular Age-related Macular Degeneration (nAMD)United States